Cardiovascular Diseases

2026 Second Universal Definition of Heart Failure

The Second Universal Definition of Heart Failure (HF) introduces a standardized global framework that updates how HF is defined, classified, prevented, and managed, with the goal of improving patient care and cardiovascular health worldwide. Recognizing the growing burden of HF and the limitations of previous definitions, international cardiac societies and foundations refined the concept of HF and its precursor stage, stage B (pre-HF), to better identify individuals at risk before symptoms develop. The new definition moves away from rigid left ventricular ejection fraction thresholds and instead classifies HF into reduced, preserved, and improved ejection fraction categories, reflecting clinical realities more accurately. It also proposes a universal classification of HF causes and emphasizes that HF is a dynamic condition, with patients potentially experiencing improvement, remission, or recovery over time. In addition, the document highlights the important roles of comorbidities, healthcare access, social determinants of health, and geographic disparities in shaping HF risk and outcomes. By establishing consistent terminology and a comprehensive classification system, this updated consensus aims to strengthen HF prevention, facilitate earlier diagnosis, improve treatment strategies, and support research and public health efforts across the globe. Source: https://www.jacc.org/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.